RxDoctor Payments Data

James Guarino, MD

Cardiovascular Disease · Doylestown, PANPI 1679572713

Payments from drug & device makers

$4,992in general payments, 2019–2025

Across 318 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$952
  • Johnson & Johnson$803
  • E.r. Squibb & Sons, L.L.C.$587
  • Amgen$473
  • Pfizer$332
  • Boehringer Ingelheim$267
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,970100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,992 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$238,328
Medicare patients
1,643
Services billed
4,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban589$725,060
XareltoRivaroxaban262$297,191
JardianceEmpagliflozin117$140,097
Repatha SureclickEvolocumab58$73,879
EntrestoSacubitril/Valsartan28$54,820
FarxigaDapagliflozin Propanediol14$17,891
Metoprolol Succinate565$10,127
Atorvastatin Calcium528$7,556
Rosuvastatin Calcium303$6,951
Icosapent Ethyl12$5,199
Ezetimibe146$5,039
Potassium Chloride51$4,498
Diltiazem 24hr Er (Cd)Diltiazem Hcl66$4,171
VascepaIcosapent Ethyl11$3,839
Flecainide Acetate33$3,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$332$725,060589 claims
Johnson & JohnsonXarelto$803$297,191262 claims
Boehringer IngelheimJardiance$267$140,097117 claims
NovartisEntresto$952$54,82028 claims
AstraZenecaFarxiga$159$17,89114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →